Robert Esmond and Alex Chung authored an article discussing small interfering RNAs (siRNAs) and potential issues surrounding its commercialization. Despite a number of patent filings claiming nanoparticle delivery of siRNA, the authors expect that companies will be able to develop proprietary siRNA drugs with few limitations.

To read the full article, download the attached PDF.

Related Industries